EHMT1 and cancer: The EHMT1/GLP and EHMT2/G9a methyltransferases are being pursued as targets for drug development, particularly as potential anti-cancer therapeutics [44, 47, 49, 52–54] including the inhibitor used in this study, UNC0642, as well as multiple additional agents, including a recently described dual inhibitor of EHMT2/G9a and the DNA methyltransferase DNMT1 [44].